La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Shockwave Medical Gestion

Gestion contrôle des critères 3/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Doug Godshall

Directeur général

US$9.5m

Rémunération totale

Pourcentage du salaire du PDG	7.6%
Durée du mandat du directeur général	7yrs
Propriété du PDG	0.3%
Durée moyenne d'occupation des postes de direction	2.3yrs
Durée moyenne du mandat des membres du conseil d'administration	5.3yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Doug Godshall a-t-elle évolué par rapport aux bénéfices de Shockwave Medical?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Mar 31 2024	n/a	n/a	US$163m
Dec 31 2023	US$9m	US$716k	US$147m
Sep 30 2023	n/a	n/a	US$244m
Jun 30 2023	n/a	n/a	US$244m
Mar 31 2023	n/a	n/a	US$241m
Dec 31 2022	US$8m	US$644k	US$216m
Sep 30 2022	n/a	n/a	US$88m
Jun 30 2022	n/a	n/a	US$55m
Mar 31 2022	n/a	n/a	US$29m
Dec 31 2021	US$7m	US$575k	-US$9m
Sep 30 2021	n/a	n/a	-US$38m
Jun 30 2021	n/a	n/a	-US$53m
Mar 31 2021	n/a	n/a	-US$71m
Dec 31 2020	US$5m	US$546k	-US$66m
Sep 30 2020	n/a	n/a	-US$65m
Jun 30 2020	n/a	n/a	-US$65m
Mar 31 2020	n/a	n/a	-US$57m
Dec 31 2019	US$2m	US$477k	-US$51m
Sep 30 2019	n/a	n/a	-US$48m
Jun 30 2019	n/a	n/a	-US$45m
Mar 31 2019	n/a	n/a	-US$44m
Dec 31 2018	US$511k	US$376k	-US$41m

Rémunération vs marché: La rémunération totale de Doug ($USD 9.48M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché German ($USD 5.47M ).

Rémunération et revenus: La rémunération de Doug a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Doug Godshall (58 yo)

7yrs

Titularisation

US$9,478,729

Compensation

Mr. Douglas E. Godshall, also known as Doug, M.B.A., is Director of Saluda Medical, Inc. He serves as Chair of the Board of Galvanize Therapeutics, Inc. since September 2022. He has been the Chief Executiv...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Douglas Godshall	President	7yrs	US$9.48m	0.29% $ 33.7m
Isaac Zacharias	President & Chief Commercial Officer	1.9yrs	US$3.23m	0.15% $ 17.4m
Daniel Hawkins	Founder and Senior Advisor	15.3yrs	pas de données	pas de données
John Adams	Co-Founder and Technical Advisor	15.3yrs	pas de données	pas de données
Renee Gaeta	Chief Financial Officer	less than a year	pas de données	0.053% $ 6.1m
Luis Morales	Senior Vice President of Global Operations	less than a year	pas de données	pas de données
Trinh Phung	Chief Accounting Officer	2.3yrs	pas de données	0.13% $ 15.5m
Debbie Kaster	Vice President of Investor Relations	less than a year	pas de données	pas de données
Hajime Tada	General Counsel & Secretary	4.9yrs	pas de données	pas de données
Robert Fletcher	Senior Vice President of Marketing & Market Access	7.8yrs	pas de données	pas de données
Dave Cox	Vice President of Sales	less than a year	pas de données	pas de données
Cathy Harnett	Senior Director of Human Resources	2.3yrs	pas de données	pas de données

2.3yrs

Durée moyenne de l'emploi

52yo

Âge moyen

Gestion expérimentée: L'équipe de direction de 36M est considérée comme expérimentée (ancienneté moyenne 2.3 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Douglas Godshall	President	7yrs	US$9.48m	0.29% $ 33.7m
Antoine Papiernik	Independent Director	10.8yrs	US$277.06k	pas de données
Frederic Moll	Independent Director	13yrs	US$273.62k	0.76% $ 88.2m
Charles Larkin	Independent Chairman of the Board	5.3yrs	US$333.62k	0.012% $ 1.4m
Laura Francis	Independent Director	5.3yrs	US$297.37k	0.011% $ 1.2m
Sara Toyloy	Independent Director	3.2yrs	US$278.62k	0.0052% $ 600.0k
Maria Sainz	Independent Director	3.8yrs	US$289.87k	0.0096% $ 1.1m
Kevin Ballinger	Independent Director	less than a year	US$508.05k	pas de données
F. Watkins	Independent Director	10.9yrs	US$278.62k	0.010% $ 1.2m

5.3yrs

Durée moyenne de l'emploi

57yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de 36M sont considérés comme expérimentés (ancienneté moyenne 5.3 ans).

Shockwave Medical Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

Shockwave Medical, Inc. Announces Termination of Employment of Renee Gaeta as Chief Financial Officer

Shockwave Medical, Inc., Annual General Meeting, May 29, 2024

Insufficient new directors

Independent Director recently sold €14m worth of stock

Shockwave Medical, Inc. Appoints Renee Gaeta as Chief Financial Officer, Effective February 5, 2024

Shockwave Medical, Inc. Appoints Nick West as Associate Chief Medical Officer

Recent updates

Shockwave Medical, Inc. Announces U.S. Launch of the Shockwave E8 Peripheral Ivl Catheter

Shockwave Medical Files Form 15

Shockwave's Common Stock Ceases Trading on NASDAQ

Shockwave Medical, Inc. Announces Termination of Employment of Renee Gaeta as Chief Financial Officer

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Shockwave Medical, Inc. (NasdaqGS:SWAV) from a group of sellers.

Shockwave Medical Withdraws Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: EPS: US$1.48 (vs US$1.07 in 1Q 2023)

Shockwave Medical, Inc., Annual General Meeting, May 29, 2024

Shockwave Medical, Inc. Announces Investigators Presented Six-Month Data from the Full Population of the Reducer-I Study

Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Shockwave Medical, Inc. (NasdaqGS:SWAV) for $13 billion.

Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Shockwave Medical, Inc. (NasdaqGS:SWAV) for $13 billion.

Insufficient new directors

Johnson & Johnson Reportedly Considers Deal for Shockwave Medical

Now 21% undervalued

New minor risk - Shareholder dilution

Independent Director recently sold €14m worth of stock

Shockwave Medical, Inc. Provides Earnings Guidance for 2024

Full year 2023 earnings released: EPS: US$4.01 (vs US$6.02 in FY 2022)

Shockwave Medical, Inc. Appoints Renee Gaeta as Chief Financial Officer, Effective February 5, 2024

Shockwave Medical, Inc. to Report Q3, 2024 Results on Nov 04, 2024

Now 21% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 27%

Shockwave Medical, Inc. Announces New Data Demonstrating One-Year Outcomes with Coronary Lithotripsy

Shockwave Medical, Inc. Provides Revenue Guidance for the Full Year 2023

Now 22% undervalued after recent price drop

Third quarter 2023 earnings released: EPS: US$0.95 (vs US$0.97 in 3Q 2022)

Shockwave Medical, Inc. Introduces Enhanced Coronary IVL Catheter in the United States

Shockwave Medical, Inc. Announces New Shockwave Coronary IVL Publications Confirm Safety and Efficacy Across Multiple Calcium Morphologies

Shockwave Medical, Inc. Appoints Nick West as Associate Chief Medical Officer

Daniel K. Puckett Notifies Shockwave Medical, Inc. of His Intention to Retire as Chief Financial Officer

New minor risk - Shareholder dilution

Shockwave Medical, Inc. Revises Revenue Guidance for the Full Year 2023

Second quarter 2023 earnings released: EPS: US$0.79 (vs US$0.71 in 2Q 2022)

Shockwave Medical, Inc.(NasdaqGS:SWAV) dropped from Russell 2000 Dynamic Index

Shockwave Medical, Inc. Appoints Kevin Ballinger to Board of Directors and Will Serve on Shockwave’s Nominating and ESG Committee and the Compensation Committee of the Board

Key Executive recently sold €548k worth of stock

Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors

Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors

First quarter 2023 earnings released: EPS: US$1.07 (vs US$0.41 in 1Q 2022)

Shockwave Medical, Inc. Revises Revenue Guidance for the Year 2023

Investor sentiment improves as stock rises 15%

Independent Director recently sold €132k worth of stock

Shockwave Medical, Inc. Provides Earnings Guidance for the Full Year 2023

Full year 2022 earnings released: EPS: US$6.02 (vs US$0.26 loss in FY 2021)

ShockWave Medical, Inc. (NasdaqGS:SWAV) entered into a definitive agreement to acquire Neovasc Inc. (TSX:NVCN) from Strul Medical Group LLC and others for $75.04 million.

ShockWave Medical, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2022 and Fiscal Year 2023

ShockWave Medical, Inc. to Report Q4, 2022 Results on Feb 16, 2023

Now 23% undervalued after recent price drop

Third quarter 2022 earnings released: EPS: US$0.97 (vs US$0.055 in 3Q 2021)

ShockWave Medical, Inc. Revises Revenue Guidance for the Year 2022

ShockWave Medical, Inc. Confirms Consistent Outcomes for IVL in the larger Prospective “Real World” Study of Patients with Heavily Calcified Peripheral Arterial Disease

Independent Director recently sold €192k worth of stock

Chief Accounting Officer recently sold €1.1m worth of stock

ShockWave Medical, Inc. Revises Revenue Guidance for the Full Year 2022

Second quarter 2022 earnings released: EPS: US$0.71 (vs US$0.012 loss in 2Q 2021)

Shockwave Medical, Inc. and Genesis MedTech Group Successfully Obtains Approval from China’S National Medical Products Administration to Market and Sell the Shockwave IVL System with the Shockwave C2 Coronary IVL Catheters and the Shockwave M5 and S4 Peripheral IVL Catheters in China

Shockwave Ivl Maintains Superiority to Angioplasty in Calcified Peripheral Disease At Two Years

First quarter 2022 earnings released: EPS: US$0.41 (vs US$0.68 loss in 1Q 2021)

ShockWave Medical, Inc. Revised Earnings Guidance for the Full Year 2022

ShockWave Medical, Inc., Annual General Meeting, Jun 23, 2022

Independent Director recently sold €357k worth of stock

Shockwave Medical, Inc. Announces the Global Commercial Availability of the Shockwave M5+ Peripheral IVL Catheter After Receiving Both CE Mark and U.S. Food and Drug Administration Clearance

Shockwave Medical Announces Japanese Regulatory Approval of Coronary IVL

Key Executive recently sold €760k worth of stock

ShockWave Medical, Inc. Announces Executive Changes

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Analyse de la rémunération des PDG

PDG

Titularisation